These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
☑
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
|
|
☐
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
|
|
Nevada
|
|
45-2859440
|
|
(State
or other jurisdiction of incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
|
Non-accelerated
filer
|
☐
(Do not check if a smaller reporting company)
|
Smaller reporting company
|
☒
|
|
|
|
Emerging
growth company
|
☐
|
|
|
|
PAGE
|
|
|
|
|
|
PART I - FINANCIAL INFORMATION
|
3
|
|
|
|
|
|
|
Item
1.
|
Financial
Statements
|
3
|
|
|
|
|
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
17
|
|
|
|
|
|
Item
3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
22
|
|
|
|
|
|
Item
4.
|
Controls
and Procedures
|
22
|
|
|
|
|
|
PART
II - OTHER INFORMATION
|
23
|
|
|
|
|
|
|
Item
1.
|
Legal
Proceedings
|
23
|
|
|
|
|
|
Item
1A.
|
Risk
Factors
|
23
|
|
|
|
|
|
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
23
|
|
|
|
|
|
Item
3.
|
Defaults
Upon Senior Securities
|
23
|
|
|
|
|
|
Item
4.
|
Mine
Safety Disclosures
|
23
|
|
|
|
|
|
Item
5.
|
Other
Information
|
23
|
|
|
|
|
|
Item
6.
|
Exhibits
|
24
|
|
|
|
|
|
|
SIGNATURES
|
25
|
|
|
|
PAGE
|
|
|
|
|
|
Condensed
Consolidated Balance Sheets as of March 31, 2017 (unaudited) and
December 31, 2016
|
|
4
|
|
|
|
|
|
Condensed
Consolidated Statements of Operations for the three months ended
March 31, 2017 and March 31, 2016 (unaudited)
|
|
5
|
|
|
|
|
|
Condensed
Consolidated Statements of Comprehensive Loss for the three months
ended March 31, 2017 and March 31, 2016 (unaudited)
|
|
6
|
|
|
|
|
|
Condensed
Consolidated Statements of Cash Flows for the three months ended
March 31, 2017 and March 31, 2016 (unaudited)
|
|
7
|
|
|
|
|
|
Notes
to Condensed Consolidated Financial Statements
(unaudited)
|
|
8
|
|
|
March
31,
2017
|
December
31,
2017
|
|
ASSETS
|
|
|
|
Current
assets
|
|
|
|
Cash
|
$
16,158
|
$
9,677
|
|
Prepaid expenses
and other current assets
|
2,437
|
32,544
|
|
Total current
assets
|
18,595
|
42,221
|
|
|
|
|
|
Investments in
associated companies
|
-
|
1,095
|
|
Total
assets
|
$
18,595
|
$
43,316
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' DEFICIENCY
|
|
|
|
Current
liabilities
|
|
|
|
Accounts
payable
|
$
4,241
|
$
16,515
|
|
Accrued expenses
and other current liabilities
|
32,500
|
37,077
|
|
Total current
liabilities
|
36,741
|
53,592
|
|
|
|
|
|
Total
liabilities
|
36,741
|
53,592
|
|
|
|
|
|
Commitments
|
|
|
|
|
|
|
|
Stockholders'
Deficiency
|
|
|
|
|
|
|
|
Preferred
stock
|
|
|
|
Authorized:
$0.001 par value, 10,000,000 shares authorized
|
-
|
-
|
|
Issued
and outstanding: nil preferred shares
|
|
|
|
Common
stock
|
|
|
|
Authorized:
$0.001 par value, 290,000,000 shares authorized
|
|
|
|
Issued
and outstanding: 187,329,355 and 187,329,355,
respectively
|
187,329
|
187,329
|
|
|
|
|
|
Additional paid-in
capital
|
8,368,582
|
8,287,292
|
|
Accumulated
deficit
|
(8,574,057
)
|
(8,484,897
)
|
|
Total stockholders'
deficiency
|
(18,146
)
|
(10,276
)
|
|
Total liabilities
and stockholders' deficiency
|
$
18,595
|
$
43,316
|
|
|
Three months
ended
March 31,
|
|
|
|
2017
|
2016
|
|
Revenues
|
|
|
|
Crowdfunding
|
$
-
|
$
72,806
|
|
The Funding
Network
|
-
|
12,049
|
|
Other
|
-
|
4,412
|
|
Total
revenues
|
-
|
89,267
|
|
Operating
expenses
|
|
|
|
Selling, general
and administrative
|
10,476
|
514,911
|
|
Professional
fees
|
86,574
|
137,035
|
|
Research and
development costs
|
-
|
17,118
|
|
Depreciation and
amortization
|
-
|
36,819
|
|
Bad debt
recoveries
|
-
|
(19,591
)
|
|
Total operating
expenses
|
97,050
|
686,292
|
|
|
|
|
|
Operating
loss
|
(97,050
)
|
(597,025
)
|
|
|
|
|
|
Other
income (expense)
|
|
|
|
Interest expense
and amortization of debt discount
|
-
|
(73,266
)
|
|
Gain on sale of
Equidam Holding B.V.
|
14,799
|
-
|
|
Other
expense
|
(6,909
)
|
-
|
|
Total other income
(expense)
|
7,890
|
(73,266
)
|
|
|
|
|
|
Net
loss
|
(89,160
)
|
(670,291
)
|
|
|
|
|
|
Net loss
attributable to noncontrolling interests
|
-
|
(7,623
)
|
|
|
|
|
|
Net
loss attributable to Symbid Corp. stockholders
|
$
(89,160
)
|
$
(662,668
)
|
|
|
|
|
|
Basic and diluted
net loss per common share
|
$
(0.00
)
|
$
(0.02
)
|
|
|
|
|
|
Weighted average
number of shares outstanding
|
|
|
|
Basic and
diluted
|
187,329,355
|
36,909,472
|
|
|
|
|
|
Share-based
compensation expense included in operating expenses:
|
|
|
|
Selling, general
and administrative
|
$
-
|
42,339
|
|
Research and
development costs
|
-
|
1,558
|
|
|
$
-
|
$
43,897
|
|
|
Three months
ended
March
31,
|
|
|
|
2017
|
2016
|
|
|
|
|
|
Net
loss
|
$
(89,160
)
|
$
(670,291
)
|
|
Other comprehensive
loss:
|
|
|
|
Foreign currency
translation income
|
-
|
32,267
|
|
Comprehensive
loss
|
(89,160
)
|
(638,024
)
|
|
|
|
|
|
Net loss
attributable to noncontrolling interests
|
-
|
(7,263
)
|
|
Foreign currency
translation loss attributable to noncontrolling
interests
|
-
|
(2,850
)
|
|
Comprehensive loss
attributable to noncontrolling interests
|
-
|
(10,473
)
|
|
|
|
|
|
Comprehensive loss
attributable to Symbid Corp. stockholders
|
$
(89,160
)
|
$
(627,551
)
|
|
|
Three months
ended
March
31,
|
|
|
|
2017
|
2016
|
|
Cash
flows from operating activities
|
|
|
|
Net
loss
|
$
(89,160
)
|
$
(670,291
)
|
|
Adjustments to
reconcile net loss to net cash
|
|
|
|
used in operating
activities
|
|
|
|
Expenses paid by
CKR under SPA
|
81,290
|
-
|
|
Gain on sale of
Equidam Holding B.V.
|
(14,799
)
|
-
|
|
Employee and
non-employee share based compensation
|
-
|
41,347
|
|
Depreciation and
amortization
|
-
|
36,819
|
|
Amortization of
debt discount
|
-
|
44,932
|
|
Provision for
doubtful accounts
|
-
|
(19,357
)
|
|
Changes
in assets and liabilities
|
|
|
|
Accounts
receivable
|
-
|
(14,401
)
|
|
Prepaid expenses
and other current assets
|
26,874
|
(96,365
)
|
|
Accounts
payable
|
(12,436
)
|
344,724
|
|
Accrued expenses
and other current liabilities
|
(1,502
)
|
1,252
|
|
Net cash used in
operating activities
|
(9,733
)
|
(331,340
)
|
|
|
|
|
|
Cash
flows from investing activities
|
|
|
|
Proceeds from sale
of Equidam Holding B.V.
|
$
15,902
|
$
-
|
|
Acquisition of
property and equipment
|
-
|
(5,784
)
|
|
Net cash provided
by (used in) investing activities
|
15,902
|
(5,784
)
|
|
|
|
|
|
Effect of exchange
rate changes on cash
|
312
|
10,883
|
|
Net
increase / (decrease) in cash
|
6,481
|
(326,241
)
|
|
|
|
|
|
Cash and cash
equivalents, beginning of period
|
9,677
|
553,696
|
|
Cash
and cash equivalents, end of period
|
$
16,158
|
$
227,455
|
|
|
|
|
|
Supplemental
cash flow disclosures
|
|
|
|
Interest
paid
|
$
-
|
$
1,349
|
|
|
March
31,
|
December
31,
|
|
|
2017
|
2016
|
|
VAT return Q4 2016/
2015
|
$
2,437
|
$
-
|
|
Revenues to be
invoiced
|
-
|
1,370
|
|
Wage tax
refund
|
-
|
3,602
|
|
Other prepaid
expenses
|
-
|
6,996
|
|
Insurance
premiums
|
-
|
13,484
|
|
Intercompany
balance Symbid Coöperatie UA and
Symbid Crowdfunding
B.V.
|
-
|
7,092
|
|
|
$
2,437
|
$
32,544
|
|
|
March
31,
|
December
31,
|
|
|
2017
|
2016
|
|
Advisory
costs
|
$
-
|
$
3,786
|
|
Holiday pay
allowance/Net salary
|
-
|
8,647
|
|
Penalty
waiver
|
14,630
|
14,630
|
|
VAT return Q4
2017/2015
|
-
|
7,028
|
|
Symbid
Coöperatie payable
|
17,870
|
-
|
|
Other current
liabilities
|
-
|
2,986
|
|
|
$
32,500
|
$
37,077
|
|
|
Three months
ended
|
|
|
|
March
31,
|
|
|
|
2017
|
2016
|
|
Revenues
|
|
|
|
Crowdfunding
|
$
-
|
$
72,806
|
|
The Funding
Network
|
-
|
12,049
|
|
Other
|
-
|
4,412
|
|
Total
revenues
|
-
|
89,267
|
|
Operating
expenses
|
|
|
|
Selling, general
and administrative
|
10,476
|
514,911
|
|
Professional
fees
|
86,574
|
137,035
|
|
Research and
development costs
|
-
|
17,118
|
|
Depreciation and
amortization
|
-
|
36,819
|
|
Bad debt expense
(recoveries)
|
-
|
(19,591
)
|
|
Total operating
expenses
|
97,050
|
686,292
|
|
|
|
|
|
Operating
loss
|
(97,050
)
|
(597,025
)
|
|
|
|
|
|
Other
income (expense)
|
|
|
|
Interest expense
and amortization of debt discount
|
-
|
(73,266
)
|
|
Gain on sale of
Equidam Holding B.V.
|
14,799
)
|
-
|
|
Other
expense
|
(6,909
)
|
-
|
|
Total other income
(expense)
|
7,890
|
(73,266
)
|
|
|
|
|
|
Net
loss
|
(89,160
)
|
(670,291
)
|
|
|
|
|
|
Net loss
attributable to noncontrolling interests
|
-
|
(7,623
)
|
|
|
|
|
|
Net
loss attributable to Symbid Corp. stockholders
|
$
(89,160
)
|
$
(662,668
)
|
|
|
|
|
|
Basic and diluted
net loss per common share
|
$
(0.00
)
|
$
(0.02
)
|
|
|
|
|
|
Weighted average
number of shares outstanding
|
|
|
|
Basic and
diluted
|
187,329,355
|
36,909,472
|
|
Exhibit Number
|
|
Description of Exhibit
|
|
31.1
|
|
Certification of
Principal Executive Officer and Pursuant to Rule
13a-14
|
|
31.2
|
|
Certification of
Principal Financial Officer Pursuant to Rule 13a-14
|
|
32.1*
|
|
CEO
Certification Pursuant to Section 906 of the Sarbanes-Oxley
Act
|
|
32.2*
|
|
CFO
Certification Pursuant to Section 906 of the Sarbanes-Oxley
Act
|
|
101.INS
|
|
XBRL
Instance Document
|
|
101.SCH
|
|
XBRL
Taxonomy Extension Schema Document
|
|
101.CAL
|
|
XBRL
Taxonomy Extension Calculation Linkbase Document
|
|
101.LAB
|
|
XBRL
Taxonomy Extension Labels Linkbase Document
|
|
101.PRE
|
|
XBRL
Taxonomy Extension Presentation Linkbase Document
|
|
101.DEF
|
|
XBRL
Taxonomy Extension Definition Linkbase Document
|
|
|
SYMBID
CORP.
|
|
|
|
|
|
|
May 12,
2017
|
By:
|
/s/ Korstiaan Zandvliet
|
|
|
Korstiaan
Zandvliet, Chief Executive Officer
|
|
|
|
|
|
|
|
SYMBID
CORP.
|
|
|
|
|
|
|
May 12,
2017
|
By:
|
/s/ Maarten van der Sanden
|
|
|
Maarten
van der Sanden, Chief Financial Officer
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|